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Background and Problem Statement  
 Irritable bowel syndrome (IBS) is a group of disorders classified as functional 
gastrointestinal disorders. IBS includes three subtypes: IBS-D (diarrhea predominant), IBS-C 
(constipation predominant), and IBS-M (mixed diarrhea and constipation).1 The specific etiology 
of IBS is unknown, but potential risk factors include genetic predisposition, altered immune 
response, elevated inflammatory response, small intestinal bacterial overgrowth, and increased 
sensitivity of the enteric nervous system.2 In North America, approximately 10% of individuals 
have symptoms associated with IBS.2 It is also a worldwide complaint with an estimated global 
prevalence of 11.2% and the rate has remained stable in the last 30 years.3 
 Currently, there is no diagnostic test and effective treatment for IBS. Physicians make a 
diagnosis after excluding all other possible organic causes of symptoms. The Rome IV Criteria is 
used to assist providers in diagnosing IBS which uses classic IBS symptoms such as abdominal 
pain, altered bowel habits, and abdominal distension/bloating for diagnosis.4 Other 
gastrointestinal (GI) disorders, such as celiac disease and lactose maldigestion, are frequently 
associated with IBS. The presently ineffective medical treatment for IBS increases the frequency 
of doctor visits, diagnostic tests, and hospitalizations for patients with IBS compared to those 
without IBS which ultimately causes financial stress on patients with IBS.  
Recent studies have indicated that fermentable oligo-, di-, and monosaccharides, and 
polyols (FODMAPs) are a significant factor in exacerbating IBS symptoms.4 The poorly 
absorbed carbohydrates become a food source for bacterial fermentation in the small intestine 
and colon. The bacterial fermentation produces gas which results in abdominal distension and 
abdominal discomfort.4 Additionally, some FODMAPs are osmotically active and can pull fluid 
into the GI tract leading to diarrhea in some.4 Understanding and assessing the dietary patterns in 
IBS may elucidate the role of diet in managing and controlling symptoms.  
The treatment of IBS focuses on improving symptoms and quality of life. A diet low in 
FODMAPs has been proposed as an efficacious dietary pattern that reduces symptoms of IBS. In 
a study by xx et al assessing dietary interventions in IBS, those following a low FODMAP diet 
reported relief of GI symptoms.13 In order to understand this phenomenon, a basic estimation of 
the FODMAP content of the diet and the corresponding food sources is of interest.  This 
information may, in turn, be used to generate appropriate nutrition intervention for IBS that 
could target specific FODMAPs in the diet. Food frequency questionnaires (FFQs) are a dietary 
assessment tool used to estimate dietary consumption over a period of 90 days.5 From this data, 
certain FODMAPs can be estimated, such as lactose and fructose. Gluten is a protein found in 
wheat, rye and barley. Unfortunately, it is not included in the analysis of FFQ data. The gluten 
content of the diet could be used as a surrogate marker for wheat, rye and barley intake which are 
all restricted on a low FODMAP diet as well due to their fructan content. Unfortunately, fructan 
content is unavailable with most FFQ data sets. Although not all FODMAPs are available 
through FFQ data, utilizing these estimates may allow us to generally compare the estimated, 
average consumption of FODMAPs between people with and without IBS. This leads to 
hypothesis generation about the dietary patterns of those with IBS as it relates to FODMAP 
content. Additionally, the Registered Dietitian Nutritionist (RDN) can utilize this data to better 
understand the dietary patterns as it relates to FODMAP intake to adjust and modify the nutrition 
interventions in this cohort.  
 
 
 Literature Review 
I. Prevalence  
 IBS is a chronic GI functional disorder that affects 9%-23% of the population across the 
world.6  According to the American College of Gastroenterology, 10%-15% percent of adult 
population in the United States suffers from IBS symptoms, but only 5%-7% percent of them 
have been diagnosed.7 In the United States, Canada, and Israel, women have about 1.5 to 2 times 
rate diagnosed for IBS symptoms than men.8  Given this high prevalence worldwide, it is 
important to understand the pathophysiology of IBS to develop effective treatments for reduction 
of gastrointestinal symptoms.    
II. Etiology and Pathophysiology  
 The etiology and pathophysiology of IBS are incompletely understood but several factors 
such as genetic/social factors, intestinal microbiota, low-grade chronic intestinal inflammation, 
abnormal GI endocrine cells, and dietary intake appear to be associated with the pathophysiology 
of IBS.4  There is no convincing evidence to support that food allergy is a causative factor in the 
pathophysiology of IBS.4,8 However, many patients have reported that their symptoms worsen by 
eating certain food items, some being those foods rich in FODMAPs such as wheat, rye, 
asparagus, sprouts, apples, figs and legumes.8  FODMAPs contained in these foods include 
fructose, lactose, fructans, galactans, glucto-oligosaccharides and polyols (sorbitol, mannitol, 
maltitol, xylitol, erythritol, polydextrose, and isomalt). The indigestible and poorly absorbed 
short-chain carbohydrates in FODMAPs have shown osmotic activity in the intestinal luminal 
and colon leading to the hypothesized change in stool consistency and frequency.10 Additionally, 
FODMAPs provide food sources for bacterial fermentation causing gas production, bowel 
distension, bloating, cramping, and diarrhea.10 Fructose is commonly found in fruits (ie., apples 
and watermelon), honey, and high-fructose corn syrup. Free fructose does not require additional 
digestion since it is absorbed by the small intestinal epithelium.  Fructose in the GI tract can lead 
to a concentration gradient where the concentration of fructose is higher in the lumen than in the 
intestinal epithelial cell allowing fructose to migrate to the terminal ileum in the GI tract leading 
to malabsorption in some with IBS and subsequent fermentation.8 Lactose naturally is found in 
mammalian milk. In most cases, lactose intolerance is a result of inadequate lactase secreted at 
the brush border.10 Fructans and galactans are oligosaccharides mainly found in wheat and 
legumes. The human intestinal tract does not secrete enzymes to digest these nutrients and break 
them down for absorption into the epithelial cells. Therefore, the unabsorbed fructans and 
galactans result in fermentation and gas formation. Lastly, polyols are sugar alcohols utilized 
mainly as sugar substitutes. Only around one-third intake of polyols is actually absorbed through 
passive diffusion in the small intestine epithelial.10 The speed of absorption of polyols is slow 
and is related to molecular size, variation of pore size of the small intestine, and pore size 
affected by mucosal disease.10 The smaller molecular size and/or larger pore size along the small 
intestine increases polyol absorption.10 Then, some diseases such as celiac disease can decrease 
the pore size leading to absorption of polyols.10  It is clear that these poorly absorbed 
carbohydrates could be partially related to the symptoms seen in IBS.  Therefore, understanding 
the absolute delivery and sources of FODMAPs in the diet can play an important role in nutrition 
therapy to improve IBS symptoms. 
Table 1. Summary of FODMAPs 
FODMAP Associated with Pathophysiology  Food Sources 
Fructose  Absorbed by the small bowl 
à a concentration gradient  
Fruit, honey, high-fructose 
corn syrup   
Lactose  Inadequate lactase secretion  Milk, cheese, yogurt 
Fructans/ Galactans No enzymes to break down 
à fermentation and gas 
formation  
Wheat, legumes  
Polyols Slowly absorbed by passive 
diffusion  
Sugar alcohols, sugar 
substitutes  
 
III. Diagnosis  
 Currently, there is no golden standard diagnostic criteria for IBS because the unknown 
etiology and pathophysiology of this syndrome. Symptoms usually are not consistent in patients 
with IBS, so criteria have been developed to identify a combination of symptoms to increase the 
accurate of diagnosing IBS. The first published diagnostic criteria are Manning in the 1979.6 
Over the last several decades, this criteria has developed into the current Rome IV criteria. The 
Rome IV criteria asserts that patients must have recurrent abdominal pain on average at least 1 
day per week during the past 3 months.9 In addition, the patient must have at least two following 
features: related to defecation, onset associated with a change in stool frequency, or onset 
associated with a change in stool consistency.9 In 2009, the American College of 
Gastroenterology (ACG) publishing a position paper stating that people are diagnosed with IBS 
if abdominal pain or discomfort occurring in association with altered bowel habits persists over a 
period of at least 3 months.6  
IV. Medical Management  
 IBS is a symptom-based disorder resulting from diverse pathologies as mentioned, so 
medical management is targeted to treat GI related symptoms such as diarrhea, constipation, 
pain, bloating, and cramping. For patients with IBS-D, the first-line agents are antidiarrheal 
medications, such as loperamide, to inhibit peristalsis, prolong gut transit, and reduce fecal 
volume.8 If patients with IBS-D do not respond to antidiarrheal medications, serotonin targeted 
agents, such as Alosetron and Ondansetron which are 5-HT3 receptor antagonists, are used to 
improve gastrointestinal motility and visceral sensation.8 Then, the third type of medication for 
IBS-D are antispasmodics which are drugs with anticholinergic or calcium channel blocking 
properties. They help gut smooth muscle to relax.8 For patients with IBS-C, the medical 
management includes fiber supplements, laxative agents, and prosecretory agents.8 Additionally, 
soluble fiber has shown greater efficacy to treat IBS-C symptoms rather than insoluble fiber.8 
Osmotic laxatives such as polyethylene glycol is a medication that pulls water into the colon to 
soften stool to improve constipation.8 Lastly, prosecretory agents stimulate intestinal fluid 
secretion to solve chronic constipation. Regardless of the subtyping, probiotics, antibiotics, and 
antidepressants are commonly prescribed to patients with IBS. Probiotics are live bacteria that 
provide general health benefits to the host.8 Rifaximin is an antibiotic has been evaluated in IBS 
for treatment of small intestinal bacterial overgrowth.  Some efficacy has been seen with these 
studies which researchers hypothesize is related to the bacterial load present in those with IBS.8 
Antidepressants such as tricyclic antidepressants, are utilized frequently in those with IBS due to 
the effect of selective serotonin-reuptake inhibitors on mood and gastrointestinal motility. 
Despite the array of medical management available, data continues to support the efficacy of 
symptom improvement with the low FODMAP diet compared to medications. 
V. Nutritional Management 
Recently, dietary interventions to control and treat IBS symptoms have received more 
attention because people with IBS report that they are able to identify some foods triggering their 
symptoms.11 Many diets have been studied in those with IBS including a gluten-free diet, strict 
elimination diets, low lactose diets and others, but poor efficacy has abandoned their use 
worldwide until the release of the low FODMAP diet.  The low-FODMAP diet is commonly 
employed by patients with IBS. The low-FODMAP diet is designed for short-term use and the 
purposed is to identify if symptoms are related to the poor digestion and absorption of short-
chained carbohydrates. The low-FODMAP diet intervention includes of 3 distinct phases: the 
restriction or elimination phase, the reintroduction or rechallenge phase, and the maintenance or 
personalized phase.12 During the first phase, patients remove all FODMAPs from their diet for up 
to 8 weeks.12 In those reporting improved symptoms, they move to the reintroduction phase to 
identify which foods were culprits. During the third and final phase, people continue the 
consumption of FODMAPs that were well-tolerated and continue eliminating trigger foods.12  
 The impact of this dietary approach has now been studied by many researchers.  
Consistently, approximately 75% of patients with IBS experience symptom improvement when 
abdominal pain and bloating were the predominant symptoms.12 In those with constipation or 
diarrhea just over 50% respond to a low-FODMAP diet.12 Although questions still remain 
unanswered related to dietary compliance and the potential long term effects, it is still 
commonplace to start with this dietary intervention in those with a diagnosis of IBS.  
VI. Assessment of Dietary Patterns  
Fructose, lactose, and polyols are main components of FODMAPs which are important 
contributors of IBS. There are several tools to assess dietary patterns, yet no tool has been 
optimized to assess the total FODMAP content of this diet that is available in public.  The USDA 
food database provides an accessible tool that can quantify a few FODMAPs in the diet (such as 
fructose and lactose).  Given that FFQs utilize this database, using an FFQ could be considered 
for dietary analysis when attempting to quantify dietary FODMAP patterns.  Strengths of an FFQ 
includes the ability to capture the dietary pattern over a three month period, ability to capture 
episodically consumed foods, and electronic data can be quickly collected and analyzed.5  FFQs 
are traditionally utilized in the research setting because it is useful in large populations with 
potential low cost and low participant burden. However, the weakness of FFQ is that it not 
suitable for cross-cultural comparisons since it is based on American eating style and it requires 
good memory, literacy, and numerical sills.5 VioScreen® is a pictorial, web-based application of 
an FFQ which offers improved security and privacy of participant information.5 It reduces time 
and is validated for high accuracy.5 The pictures in the VioScreen® allow a more accurate 
representation of portion sizes ultimately improving the accuracy of the dietary analysis.  
Objectives 
The goal of this study is to evaluate the dietary patterns of patients with and without IBS to 
determine the average intake of fructose, lactose and polyols. With this data, we can address if 
those with IBS are consuming more or less FODMAPs in the diet to improve the RDNs 
understanding of usual dietary intake of those with IBS.  With this information, the RDN can 
optimize dietary education by understanding food sources of FODMAPs typically consumed in 
those with IBS. The following research questions will be explored:  
• What is the average consumption of fructose, lactose, and polyols in the patients with and 
without IBS as measured by food frequency questionnaire (FFQs)? 
• Do patients with IBS consumed less or more fructose, lactose, and polyols compared to 
patients without IBS as measured by FFQ? 
 
Method  
Subjects  
FFQs are offered to all patients in the outpatient Gastroenterology, Hepatology and Nutrition 
(GHN) clinic at The Ohio State University Wexner Medical Center (OSUWMC). Participants 
completing this FFQ between April 2018 to November 2019 were used to estimate average 
consumption of fructose, lactose, and polyols. Average dietary consumption of fructose, lactose, 
and polyols was compared between participants with IBS and participants without IBS. Approval 
from the Institutional Review Board (IRB) was received prior to data collection (2016H0320).  
Data Collection 
Patients within the GHN outpatient clinic at OSUWMC were all provided with a handout 
indicating their access code to the on-line FFQ. Patients completed VioScreenTM FFQ on their 
computer or other electronic devices. Charts were reviewed to confirm all GI diagnoses.  All 
dietary information, anthropometric data, exercise patterns, multivitamin use and age were self-
reported through the FFQ platform.  Any participant that was not seen in a GHN clinic was 
excluded from analysis.  
Dietary Analysis  
Data collected from VioScreenTM   was used to evaluate the dietary patterns for patients with 
or without IBS and to measure average consumption of fructose, lactose, and polyols. For the 
purpose of this study, only those with an intake > 500 kcal/day will be included. To estimate 
total polyols in the diet, a sum of erythritol, inositol, isomalt, lactitol, maltitol, mannitol, pinitol, 
sorbitol, and xylitol were used to determine total polyol consumption in the diet as these are the 
polyols available in the FFQ for analysis. Each category of FODMAPs were totaled and 
averaged to estimate the contribution of these FODMAPS within the diet.  
Statistics  
Descriptive statistics were used to describe the dietary patterns in patients with IBS and 
compare it with patients without IBS. Average daily fructose, lactose, and polyols consumption, 
and additional continuous variables were represented as means ± standard deviations.  
 Results 
Demographics and Anthropometrics 
A total of 145 participants with GI diseases completed the Vioscreen™ within the 
defined time period.  Five participants were excluded. One participant did not have a name that 
matched the date of birth in the electronic medical record, three participants did not have an 
electronic medical record at OSUWMC, and one participant had a duplicated entry. Therefore, 
the final sample size was 140 records. Of these, 82.9% participants were not diagnosed with IBS 
(n=116) and 17.1% participants were diagnosed with IBS (n=24) (see Table 1). For all 
participants (N = 140), average age was 43.0 ± 15.5 years with an average weight of 80.2 ± 22.9 
kg. Participants tended to be overweight with a BMI of 28.2 ± 7.4 kg/m2 (see Table 1). The 
results indicate majority of participants (N=140) has low activity level (n=64, 45.7%, see Table 
1). Only 54 (38.6%) participants report that they take multivitamin and 86 (61.4%) participants 
deny for it (see Table 1).  
Table 1. Demographics Characteristics 
 Dietary intake including kilocalories, macronutrient, and fiber from the VioscreenTM FFQ were 
analyzed (see Table 2). Results indicate total participants (N =140) consumed 1824.7 ± 1046.8 
kcals/day (see Table 2). Those with IBS (n = 24) consumed similar kilocalories compared to that 
of participants without IBS (n = 116) (2065.6 ± 1538.1 vs 1774.9 ± 914.7 kcal, respectively; see 
Table 2). The results show that the contribution of kilocalories coming from macronutrients by 
diagnosis of IBS are identify in two study groups. (see Figure 1).  
Table 2. Dietary Intake as Measured by VioscreenTM Report 
  Total sample (N= 140) No IBS (n = 116) IBS (n= 24) 
  Mean ± SD Mean ± SD Mean ± SD 
Kilocalorie (kcal/d)  1824.7 ± 1046.8  1774.9 ± 914.7 2065.6 ± 1538.1 
Carbohydrate (g/d)  216.2 ± 147.3 208.2 ± 131.8 254.7 ± 205.8 
Fat (g/d) 75.5 ± 46.2 73.9 ± 41.7 83.1 ± 64.0 
Protein (g/d) 73.6 ± 41.6 72.5 ± 37.2 79.0 ± 59.1 
Fiber (g/d) 19.1 ± 11.3 18.6 ± 10.3 21.3 ± 15.4 
 
Figure 1. Comparison of Macronutrients Intake Between Participants with IBS and 
without IBS
 
 
The average consumption of fructose, lactose, and polyols were collected from the FFQs 
and showed no difference in intake for any FODMAPSs in those with and without IBS (see 
Table 3). 
Table 3. FODMAPs Intake as Measured by VioscreenTM Report 
 Total sample  
(N= 140) 
No IBS  
(n = 116) 
IBS  
(n = 24) 
  Median  Mean ± SD Median  
Mean ± 
SD Median 
Mean ± 
SD 
Fructose (g/d)  18.6 
27.0 ± 
35.0 16.9 25.1 ± 34.1 23.4 36.2 ± 38.1 
Lactose (g/d)  9.4 
12.6 ± 
13.0  8.5 12.4 ± 13.5 12.6 13.7 ± 9.9 
Sum polyols 
(g/d)  0.7 0.8 ± 0.6 0.5 0.7 ± 0.6 0.8 0.9 ± 0.5 
 
Figure 2. Mean FODMAPs Intake in Participants with IBS and without IBS 
 
 The average daily fiber intake is 21.3 ± 15.4 g/d in participants with IBS (n=24) (see 
Figure 3) and 18.6 ± 10.3 g/d in participants without IBS (n=116) (see Figure 3). Both two 
study groups’ daily fiber consumption are higher than the average American fiber intake of 15-
16g17,22 (see Figure 3) and below the daily recommendation intake of 25-35g17 (see Figure 3).  It 
indicates that there is no significant difference for fiber intake between participants with IBS and 
without IBS.  
Figure 3. Mean Fiber Intake per Day  
 
Discussion 
To our knowledge, this is the first study to estimate FODMAP exposure using an FFQ in 
those with and without IBS to gain an understanding of usual dietary intake. Our population with 
IBS was slightly older (42 years of age) than other reports indicating that most patients with IBS 
report symptoms before age of 35 years.15 Based on the analysis of data that the National Health 
and Nutrition Examination Survey (NHANES) collected in 2003-2006, 32% male and 38% 
female population at age 31-50 years use MVMs.18 This was similar to our study which found 
nearly 40% of participants use MVMs.  More than half of our cohort report little to no physical 
activity. A sedentary lifestyle has been associated with IBS with those engaging in <1 hour/wk 
having 1.27 times greater probability of IBS than those with ≥1 hour/wk.21 
For the RDN practicing in a GI clinic, it is important to understand if there are significant 
differences in the dietary patterns of those with and without IBS to improve counseling 
techniques and the delivery of dietary interventions.  It is unknown if those patients with IBS are 
already self-restricting FODMAPs prior to education due to their ability to determine 
intolerance.  It is also feasible that many patients seen in GI clinics self-restrict lactose and wheat 
due to perceived intolerance.  It is well-documented that patients with IBS self-identify and 
restrict potential food triggers11. However, this was not apparent in this cohort as there were no 
differences between the kilocalorie, macronutrient, fiber and measured FODMAP intake between 
groups.   
Dietary fiber intake is important to assess in this cohort since fiber is often adjusted my 
many patients and gastroenterologists within a GI clinic to impact bowel health.  Average dietary 
fiber intake was higher than that of the typical American diet which is 15-16 g/day for all 
individuals 2 years and older in 2009-2010 based on NHANES.22 However, FFQ data can 
overestimate energy intakes because of the length of the questionnaire and participants’ abilities 
to estimate accurately the portion size of foods in the lists.23 Therefore, overestimated energy 
intake can lead the over-reported fiber intake as part of total energy intake. Additionally, people 
tend to over-report their intake of healthy foods (such as vegetables) and underreport unhealthy 
foods (such as candy) which can also impact fiber estimates.23    
Specific FODMAP intake for the American population was unavailable for comparison; 
however, data reported in the literature allows us to have some discussion about comparisons of 
FODMAP intake in those with IBS.  Specifically, our data indicates the average intake of 
fructose is quite variable at 36.2 ± 38.1 g/day in those with IBS. The typical American diet 
contains fructose mainly as caloric sweeteners as high fructose corn syrup with the average 
intake of fructose increased from 37 g/d to 49 g/d from 1977 to 2005.16 Although our average 
fructose intake is less than that reported in the 2005 data, the dietary source is unknown.  High 
fructose corn syrup is rapidly fermented by the GI tract and can lead to symptoms of IBS.  Usual 
lactose consumption in Americans is unavailable; however, recommendations for dairy 
consumption for those following a 2000 kcal diet is 2.5-3 servings per day which is equivalent to 
30-36 g of lactose per day since 1 cup milk contains 12 g lactose.24,25 However, based on the data 
collected by NHANES 2009-2010, the average Americans ages 2 and older take 1.9 servings of 
dairy products daily which equates to 22.8g of lactose per day.26 This is not consistent with our 
cohort as our participants were consuming nearly 50% less than this estimate. Initial hypotheses 
would include that lactose intake is lower in a GI population compared to others given the 
spectrum of luminal diseases seen in clinic.  Polyols are not considered an essential nutrient for 
inclusion in the American diet and usual intake in a US population is unknown.  Reports in 
literature show that 10 to 20 g of sorbitol per day can lead to 90% and 100% of those in a healthy 
population to experience malabsorption, respectively.27 In patients with IBS, 5 g of sorbitol 
shows increased malabsorption.28 Our subjects consumed 0.8 g/day on average which is less than 
these reports indicated that perhaps this population is again already self-restricting these 
carbohydrates due to the impact on their GI symptoms.   
With average consumption of FODMAP intake identified, RDNs can understand the 
restrictive nature of a low FODMAP diet compared to habitual intake.  These findings highlight 
that those in a GI clinic consume less lactose and polyols than the typical American population, 
indicated that there is already some restriction despite a diagnosis of IBS.  Additionally, the use 
of the low FODMAP diet is being investigated in other GI conditions outside of IBS and perhaps 
these conditions are already self-restricting FODMAPs as well.  Understanding dietary patterns 
in a GI population allows the RDN to target problem areas and reduce the time length of 
counseling on this complex dietary approach. In some clinics, the FFQ could be implemented as 
standard of care so that the RDN has this dietary pattern information available to assist with the 
consultation.  In those clinics where this is not feasible, this research enhances the understanding 
of usual dietary patterns compared to other GI patients and supports that patients with IBS, 
although they may be self-restricting foods, they are not reducing overall FODMAP content of 
the diet.  This should be replicated in other non-GI populations since food restrictions are not 
uncommon in many GI diagnoses.  It could be hypothesized that overall FODMAP intake is 
lower in GI patients compared to healthy controls.   
 
Limitations 
Based on our knowledge, this is the first study to estimate FODMAP exposure using an FFQ in 
those with and without IBS to gain an understanding of usual dietary intake from a large sample 
size of 140 participants. However, the sample of those with IBS was small compared to our non-
IBS group.  Recruiting a larger sample of those with IBS might significantly change the averages 
reported here.  It is unknown if these patients were already adjusting their dietary intake after an 
RDN consult which can potentially skew this data.  Understanding changes in dietary patterns 
before and after an RDN consult would be beneficial for clarifying differences in these groups. 
 
Future Research 
Future research should focus on elucidating the food sources of FODMAPs in the dietary 
pattern of those with and without IBS.  It is likely that we already restricting big classes of 
FODMAPs (ie., lactose and polyols) that hidden food sources could be related to continued 
symptoms identified in the IBS population.  
 
Conclusion 
Data states that high FODMAP foods are associated with the IBS gastrointestinal 
symptoms. In analyzing the dietary patterns of patients with and without IBS, this study found 
that patients with IBS do not consume significantly less fructose, lactose, and polyols compared 
to patients without IBS.  However, the total population appears to consume much less than what 
is reported in NHANES data. RDNs should evaluate the dietary patterns before the education of 
low-FODMAPs to ensure the education is targeting patient-specific high FODMAPs foods or 
potential trigger foods.   
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